Cargando…

Schizophrenia Outpatient Health Outcomes study: twelve-month findings

BACKGROUND: The purpose of this study was to assess the 12-month outcomes associated with naturalistic antipsychotic treatment of patients participating in the Schizophrenia Outpatient Health Outcomes (SOHO) study. METHODS: SOHO is a 3-year, prospective, observational study of the health outcomes as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novick, Diego, Ascher-Svanum, Haya, Haro, Josep Maria, Bertsch, Jordan, Takahashi, Michihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045007/ https://www.ncbi.nlm.nih.gov/pubmed/27774015 http://dx.doi.org/10.2147/POR.S26552

Ejemplares similares

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum, Haya, et al.
Publicado: (2014)

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study
por: Ascher-Svanum, Haya, et al.
Publicado: (2013)

Empirically driven definitions of “good,” “moderate,” and “poor” levels of functioning in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Ye, Wenyu, et al.
Publicado: (2012)

Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study
por: Hong, Jihyung, et al.
Publicado: (2012)

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study
por: Ye, Wenyu, et al.
Publicado: (2012)

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
por: Ye, Wenyu, et al.
Publicado: (2011)

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
por: Ye, Wenyu, et al.
Publicado: (2012)

Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study
por: Brugnoli, Roberto, et al.
Publicado: (2012)

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
por: Olfson, Mark, et al.
Publicado: (2007)

Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study
por: Novick, Diego, et al.
Publicado: (2015)

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example
por: Faries, Douglas E, et al.
Publicado: (2009)

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study
por: Cuyún Carter, Gebra B, et al.
Publicado: (2011)

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2005)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2004)

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
por: Faries, Douglas E, et al.
Publicado: (2009)

Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
por: Peng, Xiaomei, et al.
Publicado: (2011)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials
por: Stauffer, Virginia, et al.
Publicado: (2009)

Predictors of switching antipsychotic medications in the treatment of schizophrenia
por: Nyhuis, Allen W, et al.
Publicado: (2010)

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
por: Liu-Seifert, Hong, et al.
Publicado: (2011)

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia
por: Chen, Lei, et al.
Publicado: (2013)

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration
por: Shi, Lizheng, et al.
Publicado: (2009)

Costs of treating patients with schizophrenia who have illness-related crisis events
por: Zhu, Baojin, et al.
Publicado: (2008)

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2010)

The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy
por: Montgomery, William, et al.
Publicado: (2013)

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

The cost of relapse and the predictors of relapse in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2010)

Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia
por: Liu-Seifert, Hong, et al.
Publicado: (2007)

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study
por: Haynes, Virginia S, et al.
Publicado: (2012)

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Sex differences in the course of schizophrenia across diverse regions of the world
por: Novick, Diego, et al.
Publicado: (2016)

Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder
por: Novick, Diego, et al.
Publicado: (2017)

Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?
por: Montgomery, William, et al.
Publicado: (2014)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians
por: Chen, Jian, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_e55k3sqjsscfcij34jrn5t09vd